Name
*
First Name
Last Name
Email
*
example@example.com
Degree(s)
*
Institution
Country
1. Which of the following statements is correct?
*
a. Only 10-20% of HCM cases are identified clinically
b. HCM mortality has not changed over time
c. Clinical phenotypes of oHCM and HFpEF are quite similar
d. Mortality in HFpEF is increasing
2. What statement is correct about the pathophysiology and treatment of hypertrophic cardiomyopathy?
*
a. In HCM, the most common genetic variants affect mitochondria
b. In HCM, genetic variants often reduce force of contraction at the myofilaments
c. Cardiac myosin inhibitors stabilize the so-called 'super-relaxed state' (SRX) of myofilaments and thereby, reduce contractility
d. In animal models of HCM, the cardiac myosin inhibitor MYK-461 (i.e., mavacamten) increases force generation at the myofilaments
3. According to the AHA/ACC 2024 guidelines for management of HCM, which is the recommended approach in patients with obstructive HCM and persistent symptoms despite treatment with betablockers?
*
a. Start disopyramide, considering myosin inhibitors (CMI) as second line agents before resorting to invasive septal reduction therapies (SRT)
b. Initiate a discussion regarding pharmacological options (CMIs or disopyramide) as an alternative to SRTs
c. Consider CMIs only if SRTs fail
d. Consider initiating a combination of CMIs and dosopyramide
Submit
Should be Empty: